A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab... Breast Cancer Res Treat (2017) 165:375–382 DOI 10.1007/s10549-017-4310-9 CLINICAL TRIAL A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2- amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104) 1 2 2 1,3 • • • • Lori J. Goldstein Fengmin Zhao Molin Wang Ramona F. Swaby 4 1,5 6,7 4 • • • • Joseph A. Sparano Neal J. Meropol Kapil N. Bhalla Christine M. Pellegrino 1 8 9,10 11,12 • • • R. Katherine Alpaugh Carla I. Falkson Paula Klein George W. Sledge Received: 17 May 2017 / Accepted: 23 May 2017 / Published online: 16 June 2017 Springer Science+Business Media New York 2017 Abstract HER2-overexpressing metastatic breast cancer with tras- Purpose Suberoylanilide hydroxamic acid (SAHA; tuzumab-resistant progressive disease. vorinostat), a small molecule inhibitor of histone deacety- Methods In Phase I, the SAHA dose was modified in lase, attenuates signaling pathways known to confer tras- cohorts of 3–6 patients to find the dose level at which 0 or 1 tuzumab resistance. A combination of SAHA and patients experienced a dose-limiting toxicity (DLT) during trastuzumab may be a promising strategy http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)

Loading next page...
 
/lp/springer_journal/a-phase-i-ii-study-of-suberoylanilide-hydroxamic-acid-saha-in-2Dye1OUhrP
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media New York
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4310-9
Publisher site
See Article on Publisher Site

Abstract

Breast Cancer Res Treat (2017) 165:375–382 DOI 10.1007/s10549-017-4310-9 CLINICAL TRIAL A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2- amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104) 1 2 2 1,3 • • • • Lori J. Goldstein Fengmin Zhao Molin Wang Ramona F. Swaby 4 1,5 6,7 4 • • • • Joseph A. Sparano Neal J. Meropol Kapil N. Bhalla Christine M. Pellegrino 1 8 9,10 11,12 • • • R. Katherine Alpaugh Carla I. Falkson Paula Klein George W. Sledge Received: 17 May 2017 / Accepted: 23 May 2017 / Published online: 16 June 2017 Springer Science+Business Media New York 2017 Abstract HER2-overexpressing metastatic breast cancer with tras- Purpose Suberoylanilide hydroxamic acid (SAHA; tuzumab-resistant progressive disease. vorinostat), a small molecule inhibitor of histone deacety- Methods In Phase I, the SAHA dose was modified in lase, attenuates signaling pathways known to confer tras- cohorts of 3–6 patients to find the dose level at which 0 or 1 tuzumab resistance. A combination of SAHA and patients experienced a dose-limiting toxicity (DLT) during trastuzumab may be a promising strategy

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Jun 16, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off